MEK Inhibitor-Associated Ocular Hypertension

Abstract

Mitogen-activated protein kinase kinase (MEK) inhibitors are targeted anti-cancer agents that are prescribed to treat a broad range of cancers. Despite their strong efficacy profile, MEK inhibitors have been associated with ocular toxicities, most notably, self-limited serous detachments of the neurosensory retina. In this report, we outline three cases of a rarely documented toxicity, MEK inhibitor-associated ocular hypertension.